Skip to main content
. 2023 Sep 19;114(12):4664–4676. doi: 10.1111/cas.15966

FIGURE 4.

FIGURE 4

TAS‐102 and MK1775 show potent antitumor effects on esophageal squamous cell carcinoma xenograft tumors. Nude mice bearing TE‐8 xenograft (A) and patient‐derived xenograft (PDX) (C) were administered a vehicle (●), MK‐1775 at 30 mg/kg (■), trifluridine (FTD)/tipiracil (TPI) at 200 mg/kg (▲), FTD/TPI + MK‐1775 (▼), and oral gavage, five times weekly, n = 12–13 per arm. Mean relative tumor volumes +/− SE are shown. Two‐way analysis of variance (ANOVA) was used for the statistical analysis. (B) Body weight from the same group as shown in (A) was monitored during the study. Mean relative tumor volumes +/− SE are shown. (D) Body weight from the same groups as shown in (C). (E) Hematoxylin and eosin (H&E) images of PDX#5 tumor tissues in each treatment group on day 29 (scale bar, 1000 μm) and immunohistochemical (IHC) staining images for γ‐H2AX on day 29 (scale bar, 100 μm). (F) γ‐H2AX positively stained nuclei were counted in eight random fields from two representative slides in each group. ****p < 0.0001.